Myelofibrosis (MF) Clinical Trials

8 recruitingLast updated: June 18, 2026

There are 8 actively recruiting myelofibrosis (mf) clinical trials across 4 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable. Top locations include New York, New York, United States, Belfast, United Kingdom, Bologna, Italy. Updated daily from ClinicalTrials.gov.


Myelofibrosis (MF) Trials at a Glance

8 actively recruiting trials for myelofibrosis (mf) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in New York, Belfast, and Bologna. Lead sponsors running myelofibrosis (mf) studies include Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas, Icahn School of Medicine at Mount Sinai, and Azienda Ospedaliero-Universitaria di Parma.

Browse myelofibrosis (mf) trials by phase

Treatments under study

About Myelofibrosis (MF) Clinical Trials

Looking for clinical trials for Myelofibrosis (MF)? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Myelofibrosis (MF) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Myelofibrosis (MF) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Primary myelofibrosis (PMF)Post-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis+3 more
Prelude Therapeutics100 enrolled5 locationsNCT07469891
Recruiting
Early Phase 1

Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined

Myelofibrosis (MF)
University of Kansas Medical Center20 enrolled1 locationNCT06414681
Recruiting
Phase 2

Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia

Myelofibrosis (MF)
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas30 enrolled13 locationsNCT07394153
Recruiting
Phase 1Phase 2

A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors

Myelofibrosis (MF)
iOnctura26 enrolled11 locationsNCT06887803
Recruiting
Not Applicable

A New Diagnostic Algorithm to Non-invasively Track Fibrotic Changes in Myeloproliferative Neoplasms Based on C-C Chemokine Receptor 2 Detection. From Flow Cytometry to the Development of Targeted Positron Emission Tomography Molecular Imaging. Pre-clinical Studies and First In-human Proof of Concept

Myelofibrosis (MF)
Azienda Ospedaliero-Universitaria di Parma265 enrolled1 locationNCT07419178
Recruiting

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Primary myelofibrosis (PMF)Myeloproliferative DisordersMyelofibrosis+49 more
MPN Research Foundation5,000 enrolled2 locationsNCT07362225
Recruiting
Phase 1Phase 2

Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)Myelofibrosis (MF)
M.D. Anderson Cancer Center66 enrolled1 locationNCT07128381
Recruiting
Phase 2

MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial

Myelofibrosis (MF)Essential Thrombocythemia, ETPolycythemia Vera (PV)
Icahn School of Medicine at Mount Sinai54 enrolled1 locationNCT06541249